109 related articles for article (PubMed ID: 3328252)
1. [New aspects of macrolides: contribution of roxithromycin].
Bertrand A; Jonquet O
Rev Med Interne; 1987; 8(5):527-32. PubMed ID: 3328252
[TBL] [Abstract][Full Text] [Related]
2. Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Young RA; Gonzalez JP; Sorkin EM
Drugs; 1989 Jan; 37(1):8-41. PubMed ID: 2651088
[TBL] [Abstract][Full Text] [Related]
3. [Roxithromycin (RU 28965), a new macrolide effective against pulmonary infections].
Lachat JM; Anex JF; Regamey C
Schweiz Med Wochenschr; 1986 Dec; 116(49):1739-41. PubMed ID: 3810100
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter study of the clinical efficacy and tolerance of roxithromycin compared to erythromycin ethylsuccinate in lower respiratory tract infections].
Bertrand A; Jonquet O; Sauvaget J
Pathol Biol (Paris); 1988 May; 36(5):544-7. PubMed ID: 3043354
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic.
Chastre J; Brun P; Fourtillan JB; Soler P; Basset G; Manuel C; Trouillet JL; Gibert C
Antimicrob Agents Chemother; 1987 Sep; 31(9):1312-6. PubMed ID: 3674843
[TBL] [Abstract][Full Text] [Related]
6. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers.
Paulsen O; Nilsson LG; Saint-Salvi B; Manuel C; Lunell E
Pharmacol Toxicol; 1988 Oct; 63(4):215-20. PubMed ID: 3194342
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of macrolides.
Nilsen OG
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():81-8. PubMed ID: 3323170
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of roxithromycin: a laboratory evaluation.
Chantot JF; Bryskier A; Gasc JC
J Antibiot (Tokyo); 1986 May; 39(5):660-8. PubMed ID: 3733515
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes].
Dubreuil L; Devos J; Romond C; Bryskier A
Pathol Biol (Paris); 1986 May; 34(5):440-4. PubMed ID: 3534717
[TBL] [Abstract][Full Text] [Related]
10. Activity of macrolides against organisms responsible for respiratory infection with emphasis on Mycoplasma and Legionella.
Hara K; Suyama N; Yamaguchi K; Kohno S; Saito A
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():75-80. PubMed ID: 3429389
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.
Czinn S; Carr H; Aronoff S
Antimicrob Agents Chemother; 1986 Aug; 30(2):328-9. PubMed ID: 3767346
[TBL] [Abstract][Full Text] [Related]
12. The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.
Felmingham D; Robbins MJ; Sanghrajka M; Leakey A; Ridgway GL
Drugs Exp Clin Res; 1991; 17(2):91-9. PubMed ID: 1650694
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450: comparison with troleandomycin and erythromycin.
Delaforge M; Sartori E; Mansuy D
Chem Biol Interact; 1988; 68(3-4):179-88. PubMed ID: 3265076
[TBL] [Abstract][Full Text] [Related]
14. Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overview.
Gentry LO
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():145-52. PubMed ID: 3323166
[TBL] [Abstract][Full Text] [Related]
15. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin.
Anderson R; Van Rensburg CE; Jooné G; Lukey PT
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():57-68. PubMed ID: 3429387
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of roxithromycin in paediatrics.
Bégué P; Kafetzis DA; Albin H; Safran C
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():101-6. PubMed ID: 3323162
[TBL] [Abstract][Full Text] [Related]
17. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.
Markham A; Faulds D
Drugs; 1994 Aug; 48(2):297-326. PubMed ID: 7527329
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 1. Uptake of 3H-macrolides by human macrophages.
Cuffini AM; Tullio V; Cimino F; Carlone NA
Microbios; 1989; 57(232-233):167-78. PubMed ID: 2739585
[TBL] [Abstract][Full Text] [Related]
19. [Comparative in vitro bacteriostatic and bactericidal effect of 5 macrolides: roxithromycin, erythromycin, oleandomycin, josamycin and spiramycin against 284 hospital bacterial strains].
Le Noc P; Croize J; Bryskier A; Le Noc D; Robert J
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):553-9. PubMed ID: 2797879
[TBL] [Abstract][Full Text] [Related]
20. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells.
Stout JE; Arnold B; Yu VL
J Antimicrob Chemother; 1998 Feb; 41(2):289-91. PubMed ID: 9533475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
